XCNQ
LOBE
Market cap8mUSD
, Last price
CAD
Name
Lobe Sciences Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
61.69%
Rev. 5Y
-29.35%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
-100.00%
Net income
-4m
L+0.08%
CFO
-1m
L+206.33%
Earnings
Dec 28, 2026
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Lobe Sciences Ltd. is a life sciences company focused on researching and advancing psychedelic-based medicines. Their primary therapeutic development involves psilocybin-derived treatments combined with N-acetylcysteine, specifically for addressing mild traumatic brain injuries (mTBI) and post-traumatic stress disorder (PTSD). Additionally, they engineer specialized devices aimed at enhancing the efficiency of drug administration. This organization, headquartered in Vancouver, Canada, underwent a name change from Greenstar Biosciences Corp. to Lobe Sciences Ltd. in November 2020.
Key people
Frederick Sancilio
Executive Chairman of the Board, Chief Executive Officer · since 2024
Charles Goulburn
President, Director · since 2024
Yong Yao
Chief Financial Officer, Executive Vice President · since 2025
Brian Zasitko
Chief Financial Officer · since 2020
Nick Karakochuk
Director · since 2026
Harry Jacobson
Independent Director · since 2024
Wesley Ramjeet
Independent Director · since 2024
Legal address
700 West Georgia Street
25th Floor
Vancouver, BC V7Y 1B3
CA
25th Floor
Vancouver, BC V7Y 1B3
CA
Headquarters
639 - 5th Avenue SW
Suite 1250
Calgary, AB T2P 0M9
CA
Suite 1250
Calgary, AB T2P 0M9
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑08 | 2024‑08 | 2023‑08 | 2022‑08 | 2021‑08 | 2020‑08 | 2019‑08 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||